| 84.89 Data as of May 17 |  +0.97 / +1.16%Today’s Change | 27.30 Today|||52-Week Range 95.85 | +46.92% Year-to-Date |
| ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up May 15 / TheStreet.com | Pharmacyclics Rises On Unusually High Volume (PCYC) May 13 / TheStreet.com |
| ASCO '13 Preview: Gilead's Big Cancer Debut May 15 / TheStreet.com | 3 Biotech Stocks Spiking With Big Volume May 13 / TheStreet.com |
| Previous close | 83.92 |
| Today’s open | 84.37 |
| Day’s range | 83.06 - 85.06 |
| Volume | 838,440 |
| Average volume (3 months) | 807,220 |
| Market cap | $6.2B |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +69.10% |
| Revenue growth (last year) | +895.87% |
| P/E ratio | 499.4 |
| Price/Sales | 45.78 |
| Price/Book | 44.54 |
| Today’s change | Today’s % change | |
|---|---|---|
| ELNElan Corporation PLC | +0.08 | +0.69% |
| RDYDr.Reddy's Laborator... | -0.61 | -1.58% |
| HSPHospira Inc | +0.02 | +0.06% |
| ONXXOnyx Pharmaceuticals... | +0.30 | +0.31% |
| Next reporting date | August 28, 2013 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $82.0M |
| Annual profit (last year) | $12.0M |
| Net profit margin | 14.62% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Robert W. Duggan |
Chief Operating Officer Mahkam Zanganeh, MD, MBA |
Corporate headquarters Sunnyvale, California |
.
